Trials / Terminated
TerminatedNCT00742482
Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy
A Phase III Study With Freeze Dried HL10, Three Dosages of 200 mg/kg Ideal Body Weight Versus Standard Therapy in ALI/ARDS Patients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 418 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of three doses of HL 10 given at fixed time intervals compared to standard therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL 10 | Freeze dried HL 10 |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2005-01-01
- Completion
- 2005-06-01
- First posted
- 2008-08-27
- Last updated
- 2025-02-24
Locations
13 sites across 12 countries: Austria, Belgium, Canada, Denmark, Finland, France, Germany, Netherlands, Norway, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00742482. Inclusion in this directory is not an endorsement.